Navigate Up
Sign In

Myelodysplastic Syndrome and Myeloproliferative Disorders Clinic

If you have a myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN)or another bone marrow failure disorder, Rush can help. We welcome patients seeking treatment or a second opinion after any of the following diagnoses:

-- Myelodysplastic syndromes (MDS)

-- MDS/MPN overlap syndromes, including chronic myelomonocytic leukemia

-- Myelofibrosis 

-- Polycythemia vera

-- Essential thrombocythemia​

-- Aplastic anemia

-- Paroxysmal nocturnal hemoglobinuria (PNH)


These disorders are closely related and uncommon. They also cause different symptoms in different people, so it takes an experienced specialist to properly diagnose and treat them.

At Rush, Jamile Shammo, MD, focuses exclusively on rare blood and bone marrow disorders. She leads a team of ​experts who meet every two weeks to discuss new patients' diagnoses and treatment plans.


Wei-Tong Hsu, MD, received her medical degree from the Beijing Medical College and had completed her Clinical Cytogenetics Fellowship at Cedars-Sinai Medical Center, University of California at Los Angeles (UCLA) Intercampus Medical Genetics Training Program. She joined Department of Pathology at Rush University Medical Center after completing her fellowship in Clinical Cytogenetics. Dr. Hsu is a board certified clinical cytogeneticist by the American Board of Medical Genetics.

Dr. Hsu is currently the director for the Clinical Cytogenetics Laboratory at Department of Pathology in Rush University Medical Center.  She reviews a wide spectrum of cytogenetic tests including chromosome, FISH, and genomic microarray analyses, on constitutional and oncological samples.

Dr. Hsu’s interests focus on understanding the cytogenetic basis of genetic disorders, cytogenetic and molecular genetic changes in neoplasm, and molecular karyotyping and microarray studies in constitutional disorders and neoplasm.

  • Pathology-Anatomic
Board Certification:
  • Anatomic Pathology
Faculty Rank: Associate Professor
Medical or Graduate Education: Albert Einstein College of Medicine
Residency: McGaw Medical Center of Northwestern University - Anatomic Pathology
  Rush University Medical Center - Anatomic Pathology
Fellowship: Stanford Hospital and Clinics - Membrane Pathobiology
Clinical Expertise:
  • Bone cancer
  • Leukemias, acute and chronic
  • Lymphoma
  • Myelodysplastic syndrome
  • Myeloproliferative disorders
  • Soft tissue tumors​ 

Jamile M. Shammo, MD, is an associate professor of medicine and pathology, Section of Hematology and Stem Cell Transplantation, Division of Hematology/Oncology, at Rush University Medical Center in Chicago, Illinois, where she spearheads the MDS/MPN/Bone Marrow Failure Program. She is involved in research activities and administration, as a principal investigator of clinical trials in her area of expertise, and as a co-chair for the protocol review and monitoring committee at Rush Cancer Institute. She is recognized nationally for her expertise in bone marrow failure syndromes, and was chosen to serve as a national coordinator for the PNH registry. Dr. Shammo earned her medical degree with honors from Aleppo Medical School in Syria, after which she pursued further education in the US and completed residencies in Pathology and Internal Medicine at McGaw Medical Center of Northwestern University in Evanston, Illinois, as well as a 3-year fellowship in the Division of Hematology/Oncology at University of Chicago.

 Dr Shammo is board certified in anatomic and clinical pathology, internal medicine, and hematology, and board eligible in oncology. Dr Shammo is a fellow of the American Society of Clinical Pathologists and American College of Physicians. She received the Department of Medicine Service and Teaching Award from Rush University Medical Center in 2003. Dr. Shammo speaks fluent Arabic.

 Dr Shammo has authored or coauthored over 100 publications, including abstracts, posters, book chapters and online CME activities, as well as articles published in Blood, American Journal of Hematology, Journal of Clinical Oncology, Clinical Lymphoma, Journal of Heart and Lung Transplantation, Cytotherapy, and American Journal of Clinical Pathology, among others. Additionally, she served as a reviewer for several medical journals and as an editor for the Journal of Clinical Oncology. She has designed and is currently involved as principal investigator for many clinical trials related to chronic myelogenous leukemia, myeloproliferative neoplasms, paroxysmal nocturnal hemoglobinuria, and myelodysplastic syndromes. As an invited speaker, Dr Shammo has presented her research at national and international meetings and conferences.


What Your Diagnosis Means

These disorders have more in common than complicated names. In each case, bone marrow does not make enough healthy blood cells. (Bone marrow, a spongy substance inside your bones, normally works as a cell “factory.”)

But each diagnosis means something different:

      • MDS means you don't have enough of at least one type of blood cell. It also means that some of your blood cells are abnormally shaped.
      • Aplastic anemia means you do not have enough bone marrow to make the right amount of blood cells.
      • PNH means that your red blood cells are missing a protein they need to survive. As a result, your immune system breaks them apart.
      • MDS/MPN overlap syndromes are like MDS in some ways and like myeloproliferative neoplasms (MPN) in others.    

All myeloproliferative neoplasms involve having too many blood cells. But each diagnosis means something different:

      • Polycythemia vera means you have too many red blood cells. You might also have too many white blood cells or platelets (a kind of cell that helps your blood to clot).
      • Essential thrombocythemia means your blood has too many platelets.
      • Myelofibrosis means you have abnormal blood cells that grow too quickly and take over your bone marrow (a spongy material inside your bones that produces cells). This causes scar tissue to grow in your bone marrow and stops it from working normally. 

Treatment Options

Before your appointment, the team at Rush will meet to talk about your care. They will look at any blood or bone marrow tests you have had and discuss the treatments most likely to work for you.

Depending on your condition, you might need one or more of the following:

After you arrive, Jamile Shammo, MD, will examine you, explain your options and work with you to create a treatment plan that meets your needs. If you wish, the team at Rush will be happy to work with your regular hematologist to carry out your treatment.

Second Opinions

Rush welcomes patients seeking second opinions. If you have been diagnosed with an MDS or another bone marrow failure disorder, you may want to get a second opinion to make sure that the diagnosis is accurate and that your treatment plan is the best one for you.

Clinical Trials

Doctors at Rush are conducting research on new treatments for bone marrow failure disorders. Through clinical trials, they can offer some patients medications that are not widely available otherwise.

In addition to clinical trials, doctors at Rush participate in registry studies, which involve collecting information about many patients to help improve understanding of a condition. Jamile Shammo, MD, is one of four physicians nationwide in charge of the PNH registry, an international research project whose goal is to help doctors and researchers learn more about PNH.

Accreditation and Recognition

Rush Cancer Center MDS Clinic
1725 W. Harrison St.
Professional Building II
Suite 1010
Chicago, IL 60612
Phone: (312) 942-5544
Driving Directions

Practice Resources

Forgot MyChart Username? Forgot Password?